1. Home
  2. SLDB vs HQ Comparison

SLDB vs HQ Comparison

Compare SLDB & HQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$6.17

Market Cap

623.0M

Sector

Health Care

ML Signal

N/A

Logo Horizon Quantum Holdings Ltd. Class A Ordinary Shares

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$14.10

Market Cap

674.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLDB
HQ
Founded
2013
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
623.0M
674.1M
IPO Year
2017
2025

Fundamental Metrics

Financial Performance
Metric
SLDB
HQ
Price
$6.17
$14.10
Analyst Decision
Strong Buy
Buy
Analyst Count
14
2
Target Price
$18.71
★ $20.50
AVG Volume (30 Days)
★ 1.3M
94.7K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 34.97
N/A
EPS
N/A
★ N/A
Revenue
★ $8,094,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$3.79
$8.29
52 Week High
$11.45
$45.00

Technical Indicators

Market Signals
Indicator
SLDB
HQ
Relative Strength Index (RSI) 42.00 45.79
Support Level $5.38 $13.68
Resistance Level $6.77 $14.43
Average True Range (ATR) 0.46 1.11
MACD 0.12 0.06
Stochastic Oscillator 63.64 47.94

Price Performance

Historical Comparison
SLDB
HQ

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

Share on Social Networks: